Oxford BioTherapeutics, a UK-based biotechnology company focused on the development of antibody-drug conjugates (ADCs) for the treatment of cancer, has hired Eugen Leo as Head of Clinical Development.
Leo has more than 15 years of experience in Phase I–III clinical development of targeted molecules including antibodies, antibody derivatives, kinase inhibitors, vaccines and antisense molecules. He previously worked at Micromet, where he held several positions with increasing seniority and was instrumental in developing the company’s BiTE (bi-specific T-cell engager) antibody platform to clinical proof-of-concept, which received 'breakthrough therapy' designation from the FDA on 1 July. Thereafter he held senior development positions at Johnson & Johnson and Merck Serono.
'Recruiting someone of Eugen’s calibre is a key step for the company as we progress our pipeline of exciting ADC candidates into the clinic. With Eugen’s appointment, as well as the recent appointment of Keith Wilson as Chief Scientific Officer, we have an exceptionally strong team in place to accelerate the development of our novel antibody drug conjugate programs into their first clinical trials,' said Christian Rohlff, Oxford BioTherapeutics’ CEO.